Literature DB >> 6641314

Pattern of breathing in a case of generalized respiratory muscle weakness.

S Grinman, W A Whitelaw.   

Abstract

A patient with motor neuron disease is described. He had signs and laboratory data indicating generalized, symmetrical weakness, involving both inspiratory and expiratory muscle groups. The pattern of breathing involving recruitment of accessory muscles and expiratory contraction of abdominal muscles is similar to that seen in normal people at high minute ventilation, and suggests the compensating mechanism for increasing motor discharge to weak respiratory muscles is mediated centrally. Observation of this sort of respiratory activity gives a clinical clue to generalized respiratory muscle weakness.

Entities:  

Mesh:

Year:  1983        PMID: 6641314     DOI: 10.1378/chest.84.6.770

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

Review 1.  Diaphragmatic paresis: pathophysiology, clinical features, and investigation.

Authors:  G J Gibson
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

2.  Control of breathing in patients with limb girdle dystrophy: a controlled study.

Authors:  F Gigliotti; A Pizzi; R Duranti; M Gorini; I Iandelli; G Scano
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

3.  Breathing pattern and central ventilatory drive in mild and moderate generalised myasthenia gravis.

Authors:  F García Río; C Prados; E Díez Tejedor; S Díaz Lobato; R Alvarez-Sala; J Villamor; J M Pino
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

4.  Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.

Authors:  P Goti; A Spinelli; G Marconi; R Duranti; F Gigliotti; A Pizzi; G Scano
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

5.  Respiratory Failure or Impairment in Amyotrophic Lateral Sclerosis.

Authors:  Deborah F. Gelanis
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.